Complex	O
Changes	O
in	O
the	O
Innate	O
and	O
Adaptive	B:C0678209
Immunity	I:C0678209
Accompany	O
Progressive	O
Degeneration	O
of	O
the	O
Nigrostriatal	O
Pathway	O
Induced	O
by	O
Intrastriatal	O
Injection	I:C1533685
of	O
6	O
-	I:C0085196
Hydroxydopamine	I:C0085196
in	O
the	O
Rat	O
.	O

Complex	O
Changes	O
in	O
the	O
Innate	O
and	O
Adaptive	O
Immunity	I:C0678209
Accompany	O
Progressive	O
Degeneration	B:C2750821
of	O
the	O
Nigrostriatal	O
Pathway	O
Induced	O
by	O
Intrastriatal	O
Injection	I:C1533685
of	O
6	O
-	I:C0085196
Hydroxydopamine	I:C0085196
in	O
the	O
Rat	O
.	O

Complex	O
Changes	O
in	O
the	O
Innate	O
and	O
Adaptive	O
Immunity	I:C0678209
Accompany	O
Progressive	O
Degeneration	O
of	O
the	O
Nigrostriatal	O
Pathway	O
Induced	O
by	O
Intrastriatal	B:C1533685
Injection	I:C1533685
of	O
6	O
-	I:C0085196
Hydroxydopamine	I:C0085196
in	O
the	O
Rat	O
.	O

Complex	O
Changes	O
in	O
the	O
Innate	O
and	O
Adaptive	O
Immunity	I:C0678209
Accompany	O
Progressive	O
Degeneration	O
of	O
the	O
Nigrostriatal	O
Pathway	O
Induced	O
by	O
Intrastriatal	O
Injection	I:C1533685
of	O
6	B:C0085196
-	I:C0085196
Hydroxydopamine	I:C0085196
in	O
the	O
Rat	O
.	O

Complex	O
Changes	O
in	O
the	O
Innate	O
and	O
Adaptive	O
Immunity	I:C0678209
Accompany	O
Progressive	O
Degeneration	O
of	O
the	O
Nigrostriatal	O
Pathway	O
Induced	O
by	O
Intrastriatal	O
Injection	I:C1533685
of	O
6	O
-	I:C0085196
Hydroxydopamine	I:C0085196
in	O
the	O
Rat	B:C0034721
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	B:C0678209
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	B:C2750821
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	B:C0574032
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	B:C0085196
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	B:C0085196
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	B:C0034721
striatum	O
.	O

We	O
investigated	O
changes	O
in	O
innate	O
and	O
adaptive	O
immunity	I:C0678209
paralleling	O
the	O
progressive	O
nigrostriatal	O
damage	I:C2750821
occurring	O
in	O
a	O
neurotoxic	O
model	O
of	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
(	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
)	O
based	O
on	O
unilateral	O
infusion	O
of	O
6	O
-	I:C0085196
hydroxydopamine	I:C0085196
(	O
6	O
-	I:C0085196
OHDA	I:C0085196
)	O
into	O
the	O
rat	O
striatum	B:C0162512
.	O

A	O
time	B:C0936012
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	B:C1326120
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	B:C0206116
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	B:C0004112
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	B:C0206116
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	B:C0024432
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	B:C4086555
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	B:C0024264
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	B:C0332448
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	B:C0221198
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	B:C3840684
of	O
CD8	O
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

A	O
time	O
-	I:C0936012
course	I:C0936012
analysis	I:C0936012
was	O
conducted	O
to	O
assess	O
changes	O
in	O
morphology	O
(	O
activation	O
)	O
and	O
cell	O
density	O
of	O
microglia	O
and	O
astrocytes	O
,	O
microglia	O
polarization	O
(	O
M1	O
vs.	O
M2	O
phenotype	I:C4086555
)	O
,	O
lymphocyte	O
infiltration	O
in	O
the	O
lesioned	O
substantia	O
nigra	O
pars	O
compacta	O
(	O
SNc	O
)	O
,	O
and	O
modifications	O
of	O
CD8	B:C1267843
+	I:C1267843
and	I:C1267843
subsets	I:C1267843
of	I:C1267843
CD4	I:C1267843
+	I:C1267843

T	I:C1267843
cell	I:C1267843
in	O
peripheral	B:C0229664
blood	I:C0229664
accompanying	O
nigrostriatal	O
degeneration	I:C2750821
.	O

T	I:C1267843
cell	I:C1267843
in	O
peripheral	O
blood	I:C0229664
accompanying	O
nigrostriatal	B:C2750821
degeneration	I:C2750821
.	O

Confirming	O
previous	O
results	O
,	O
we	O
observed	O
slightly	O
different	O
profiles	O
of	O
activation	B:C1326120
for	O
astrocytes	O
and	O
microglia	O
paralleling	O
nigral	O
neuronal	I:C1850496
loss	I:C1850496
.	O

Confirming	O
previous	O
results	O
,	O
we	O
observed	O
slightly	O
different	O
profiles	O
of	O
activation	O
for	O
astrocytes	B:C0004112
and	O
microglia	O
paralleling	O
nigral	O
neuronal	I:C1850496
loss	I:C1850496
.	O

Confirming	O
previous	O
results	O
,	O
we	O
observed	O
slightly	O
different	O
profiles	O
of	O
activation	O
for	O
astrocytes	O
and	O
microglia	B:C0206116
paralleling	O
nigral	O
neuronal	I:C1850496
loss	I:C1850496
.	O

Confirming	O
previous	O
results	O
,	O
we	O
observed	O
slightly	O
different	O
profiles	O
of	O
activation	O
for	O
astrocytes	O
and	O
microglia	O
paralleling	O
nigral	B:C1850496
neuronal	I:C1850496
loss	I:C1850496
.	O

For	O
astrocytes	B:C0004112
,	O
morphological	O
changes	O
and	O
cell	O
density	O
increases	O
were	O
mostly	O
evident	O
at	O
the	O
latest	O
time	O
points	O
(	O
14	O
and	O
28	O
days	O
post	O
-	I:C0241311
surgery	I:C0241311
)	O
,	O
while	O
moderate	O
microglia	O
activation	O
was	O
present	O
since	O
the	O
earliest	O
time	O
point	O
.	O

For	O
astrocytes	O
,	O
morphological	O
changes	O
and	O
cell	O
density	O
increases	O
were	O
mostly	O
evident	O
at	O
the	O
latest	O
time	O
points	O
(	O
14	O
and	O
28	O
days	O
post	B:C0241311
-	I:C0241311
surgery	I:C0241311
)	O
,	O
while	O
moderate	O
microglia	O
activation	O
was	O
present	O
since	O
the	O
earliest	O
time	O
point	O
.	O

For	O
astrocytes	O
,	O
morphological	O
changes	O
and	O
cell	O
density	O
increases	O
were	O
mostly	O
evident	O
at	O
the	O
latest	O
time	O
points	O
(	O
14	O
and	O
28	O
days	O
post	O
-	I:C0241311
surgery	I:C0241311
)	O
,	O
while	O
moderate	O
microglia	B:C0206116
activation	O
was	O
present	O
since	O
the	O
earliest	O
time	O
point	O
.	O

For	O
astrocytes	O
,	O
morphological	O
changes	O
and	O
cell	O
density	O
increases	O
were	O
mostly	O
evident	O
at	O
the	O
latest	O
time	O
points	O
(	O
14	O
and	O
28	O
days	O
post	O
-	I:C0241311
surgery	I:C0241311
)	O
,	O
while	O
moderate	O
microglia	O
activation	B:C1326120
was	O
present	O
since	O
the	O
earliest	O
time	O
point	O
.	O

For	O
the	O
first	O
time	O
,	O
in	O
this	O
model	O
,	O
we	O
described	O
the	O
time	O
-	O
dependent	O
profile	O
of	O
microglia	B:C0206116
polarization	O
.	O

Activated	B:C1326120
microglia	O
clearly	O
expressed	O
the	O
M2	O
phenotype	I:C4086555
in	O
the	O
earlier	O
phase	O
of	O
the	O
experiment	O
,	O
before	O
cell	O
death	I:C0007587
became	O
manifest	O
,	O
gradually	O
shifting	O
to	O
the	O
M1	O
phenotype	I:C0024432
as	O
SNc	O
cell	O
death	I:C0007587
started	O
.	O

Activated	O
microglia	B:C0206116
clearly	O
expressed	O
the	O
M2	O
phenotype	I:C4086555
in	O
the	O
earlier	O
phase	O
of	O
the	O
experiment	O
,	O
before	O
cell	O
death	I:C0007587
became	O
manifest	O
,	O
gradually	O
shifting	O
to	O
the	O
M1	O
phenotype	I:C0024432
as	O
SNc	O
cell	O
death	I:C0007587
started	O
.	O

Activated	O
microglia	O
clearly	O
expressed	O
the	O
M2	B:C4086555
phenotype	I:C4086555
in	O
the	O
earlier	O
phase	O
of	O
the	O
experiment	O
,	O
before	O
cell	O
death	I:C0007587
became	O
manifest	O
,	O
gradually	O
shifting	O
to	O
the	O
M1	O
phenotype	I:C0024432
as	O
SNc	O
cell	O
death	I:C0007587
started	O
.	O

Activated	O
microglia	O
clearly	O
expressed	O
the	O
M2	O
phenotype	I:C4086555
in	O
the	O
earlier	O
phase	O
of	O
the	O
experiment	B:C0681814
,	O
before	O
cell	O
death	I:C0007587
became	O
manifest	O
,	O
gradually	O
shifting	O
to	O
the	O
M1	O
phenotype	I:C0024432
as	O
SNc	O
cell	O
death	I:C0007587
started	O
.	O

Activated	O
microglia	O
clearly	O
expressed	O
the	O
M2	O
phenotype	I:C4086555
in	O
the	O
earlier	O
phase	O
of	O
the	O
experiment	O
,	O
before	O
cell	B:C0007587
death	I:C0007587
became	O
manifest	O
,	O
gradually	O
shifting	O
to	O
the	O
M1	O
phenotype	I:C0024432
as	O
SNc	O
cell	O
death	I:C0007587
started	O
.	O

Activated	O
microglia	O
clearly	O
expressed	O
the	O
M2	O
phenotype	I:C4086555
in	O
the	O
earlier	O
phase	O
of	O
the	O
experiment	O
,	O
before	O
cell	O
death	I:C0007587
became	O
manifest	O
,	O
gradually	O
shifting	O
to	O
the	O
M1	B:C0024432
phenotype	I:C0024432
as	O
SNc	O
cell	O
death	I:C0007587
started	O
.	O

Activated	O
microglia	O
clearly	O
expressed	O
the	O
M2	O
phenotype	I:C4086555
in	O
the	O
earlier	O
phase	O
of	O
the	O
experiment	O
,	O
before	O
cell	O
death	I:C0007587
became	O
manifest	O
,	O
gradually	O
shifting	O
to	O
the	O
M1	O
phenotype	I:C0024432
as	O
SNc	O
cell	B:C0007587
death	I:C0007587
started	O
.	O

In	O
parallel	O
,	O
a	O
reduction	O
in	O
the	O
percentage	O
of	O
circulating	O
CD4	B:C0039215
+	I:C0039215

T	I:C0039215
regulatory	I:C0039215
(	O
T	B:C0039215
regulatory	I:C0039215
)	O
cells	O
,	O
starting	O
as	O
early	O
as	O
day	O
3	O
post	O
-	O
6	O
-	I:C0085196
OHDA	I:C0085196
injection	O
,	O
was	O
detected	O
in	O
6	O
-	I:C0085196
OHDA	I:C0085196
-	O
injected	O
rats	O
.	O

T	I:C0039215
regulatory	I:C0039215
(	O
T	O
regulatory	I:C0039215
)	O
cells	B:C0007634
,	O
starting	O
as	O
early	O
as	O
day	O
3	O
post	O
-	O
6	O
-	I:C0085196
OHDA	I:C0085196
injection	O
,	O
was	O
detected	O
in	O
6	O
-	I:C0085196
OHDA	I:C0085196
-	O
injected	O
rats	O
.	O

T	I:C0039215
regulatory	I:C0039215
(	O
T	O
regulatory	I:C0039215
)	O
cells	O
,	O
starting	O
as	O
early	O
as	O
day	O
3	O
post	O
-	O
6	B:C0085196
-	I:C0085196
OHDA	I:C0085196
injection	O
,	O
was	O
detected	O
in	O
6	O
-	I:C0085196
OHDA	I:C0085196
-	O
injected	O
rats	O
.	O

T	I:C0039215
regulatory	I:C0039215
(	O
T	O
regulatory	I:C0039215
)	O
cells	O
,	O
starting	O
as	O
early	O
as	O
day	O
3	O
post	O
-	O
6	O
-	I:C0085196
OHDA	I:C0085196
injection	B:C1533685
,	O
was	O
detected	O
in	O
6	O
-	I:C0085196
OHDA	I:C0085196
-	O
injected	O
rats	O
.	O

T	I:C0039215
regulatory	I:C0039215
(	O
T	O
regulatory	I:C0039215
)	O
cells	O
,	O
starting	O
as	O
early	O
as	O
day	O
3	O
post	O
-	O
6	O
-	I:C0085196
OHDA	I:C0085196
injection	O
,	O
was	O
detected	O
in	O
6	B:C0085196
-	I:C0085196
OHDA	I:C0085196
-	O
injected	O
rats	O
.	O

T	I:C0039215
regulatory	I:C0039215
(	O
T	O
regulatory	I:C0039215
)	O
cells	O
,	O
starting	O
as	O
early	O
as	O
day	O
3	O
post	O
-	O
6	O
-	I:C0085196
OHDA	I:C0085196
injection	O
,	O
was	O
detected	O
in	O
6	O
-	I:C0085196
OHDA	I:C0085196
-	O
injected	O
rats	B:C0034721
.	O

Our	O
data	O
show	O
that	O
nigrostriatal	B:C2750821
degeneration	I:C2750821
is	O
associated	O
with	O
complex	O
changes	O
in	O
central	O
and	O
peripheral	O
immunity	I:C0020964
.	O

Our	O
data	O
show	O
that	O
nigrostriatal	O
degeneration	I:C2750821
is	O
associated	O
with	O
complex	O
changes	O
in	O
central	B:C0020964
and	O
peripheral	O
immunity	I:C0020964
.	O

Our	O
data	O
show	O
that	O
nigrostriatal	O
degeneration	I:C2750821
is	O
associated	O
with	O
complex	O
changes	O
in	O
central	O
and	O
peripheral	B:C0020964
immunity	I:C0020964
.	O

Microglia	B:C0206116
activation	O
and	O
polarization	O
,	O
T	O
regulatory	I:C0039215
cells	O
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	O
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	O
modification	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

Microglia	O
activation	B:C1326120
and	O
polarization	O
,	O
T	O
regulatory	I:C0039215
cells	O
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	O
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	O
modification	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

Microglia	O
activation	O
and	O
polarization	O
,	O
T	B:C0039215
regulatory	I:C0039215
cells	O
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	O
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	O
modification	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

Microglia	O
activation	O
and	O
polarization	O
,	O
T	O
regulatory	I:C0039215
cells	B:C0007634
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	O
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	O
modification	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

Microglia	O
activation	O
and	O
polarization	O
,	O
T	O
regulatory	I:C0039215
cells	O
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	B:C2986468
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	O
modification	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

Microglia	O
activation	O
and	O
polarization	O
,	O
T	O
regulatory	I:C0039215
cells	O
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	O
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	B:C3840684
modification	O
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

Microglia	O
activation	O
and	O
polarization	O
,	O
T	O
regulatory	I:C0039215
cells	O
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	O
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	O
modification	B:C0012634
in	O
Parkinson	O
's	I:C0030567
disease	I:C0030567
.	O

Microglia	O
activation	O
and	O
polarization	O
,	O
T	O
regulatory	I:C0039215
cells	O
,	O
and	O
the	O
factors	O
involved	O
in	O
their	O
cross	O
-	I:C2986468
talk	I:C2986468
should	O
be	O
further	O
investigated	O
as	O
targets	O
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
for	O
disease	O
modification	O
in	O
Parkinson	B:C0030567
's	I:C0030567
disease	I:C0030567
.	O

